When was CrestecBio founded?

CrestecBio was founded in 2021 and raised its 1st funding round 5 years after it was founded.

Where is CrestecBio located?

CrestecBio is headquartered in Tsukuba, Japan.

How many employees does CrestecBio have?

As of Sep 30, 2026, the latest employee count at CrestecBio is 3.

Is CrestecBio a funded company?

CrestecBio is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Jun 02, 2026.

When was the latest funding round of CrestecBio?

CrestecBio's latest funding was a $***** Seed round on Jun 02, 2026, with participation from 3 investors. Its primary sector is Neurology. In Japan, the Neurology sector has seen $55.5M in funding in 2026 to date.

Where does CrestecBio rank among its competitors?

CrestecBio ranks 14th amongst 32 active competitors, of which 14 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Remedium Bio, which secured $10M in Aug, 2026.

Who are the top competitors of CrestecBio?

CrestecBio's top competitors include Remedium Bio, Bioxodes and S&E bio. Among them, Remedium Bio secured the most recent funding round in August, 2026.

CrestecBio - 2026 Company Profile, Team, Funding & Competitors

CrestecBio is a seed company based in Tsukuba (Japan), founded in 2021. It operates as a Developer of treatments for brain diseases with a focus on stroke and related conditions. CrestecBio has raised $1.57M in funding. The company has 32 active competitors, including 14 funded and 4 that have exited. Its top competitors include companies like Remedium Bio, Bioxodes and S&E bio.

Company Details

Developer of treatments for brain diseases with a focus on stroke and related conditions. The lead product, CTB211, is a polymer-based nanomedicine designed to protect the brain and reduce the risk of brain damage during stroke by protecting nerve cells by eliminating reactive oxygen species.

Website: crestecbio.com
Phone Number: +81 **********

Key Metrics

Founded Year

2021

Location

Tsukuba, Japan

Stage

Seed

Total Funding

$1.57M in 1 round

Latest Funding Round

Seed, Jun 02, 2026, $*****

Investors

JST & 3 more

Ranked

14^th among 32 active competitors

Employee Count

3 as on Sep 30, 2026

Similar Companies

Remedium Bio & 41 more

View CrestecBio's full profile

CrestecBio has raised a total funding of $1.57M over 1 round. Its latest funding round was a Seed round on Jun 02, 2026 for $*****. 3 investors participated in its latest round. CrestecBio has 4 institutional investors.

Here is the list of recent funding rounds of CrestecBio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 02, 2026	1806336	Seed	1064924	2056589	1070366	3728330

Access funding benchmarks and valuations. Sign up today!

View details of CrestecBio's funding rounds and investors

CrestecBio's employee count trend

CrestecBio has 3 employees as of Sep 26. Here is CrestecBio's employee count trend over the years:

Uncover CrestecBio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of CrestecBio include Remedium Bio, Bioxodes and S&E bio. Here is the list of Top 10 competitors of CrestecBio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Remedium Bio 2020, Needham (United States), Series A	Developer of gene therapies for a broad range of diseases	$15M	LifeSpan Vision Ventures, https://hkxcapital.com ... & 10 others	57/100
2nd	Bioxodes 2013, Marche en Famenne (Belgium), Series A	Developer of novel peptide therapies for prevention of thrombosis	$45.4M	SFPI, Newton Biocapital & 3 others	55/100
3rd	S&E bio 2019, Seoul (South Korea), Series A	Developer of cell therapies for neurological disorders	$7.34M	LSK investment, Company K Partners & 2 others	49/100
4th	NuvOx Therapeutics 2008, Tucson (United States), Funding Raised	Developer of an oxygen therapeutic drug designed to reverse tissue hypoxia	-	Pasadena Angels, Military Health & 1 others	48/100
5th	Ever Supreme Bio Technology 2016, Taichung (Taiwan), Public	Developer of immune cell and stem cell therapies for multiple diseases	-	-	45/100
6th	Acticor Biotech 2013, Paris (France), Public	Developing immunotherapeutics for treating ischemic stroke	$31.4M	Newton Biocapital, GO CAPITAL & 7 others	45/100
7th	Basking Biosciences 2019, Columbus (United States), Series C	Developer of therapeutics for ischemic stroke treatment	$117M	Arch Venture Partners, Broadview Ventures ... & 9 others	44/100
8th	Argenica Therapeutics 2019, Nedlands (Australia), Public	Developer of neuroprotective therapeutics for stroke and neural injuries	-	The Australian health system	40/100
9th	Remedy Pharmaceuticals 2004, New York City (United States), Series D	Intravenous formulation for acute central nervous system conditions such as stroke (ischemic and hemorrhagic), traumatic brain injury.	$22.8M	The Vertical Group, Broadview Ventures & 4 others	40/100
10th	Guangzhou Magpie Pharmaceuticals 2016, Guangzhou (China), Series B	Developer of small molecules for the treatment of stroke and other heart diseases	$29.1M	Sangel Capital, Zhejiang Conba Pharmaceutical ... & 2 others	39/100
14th	CrestecBio 2021, Tsukuba (Japan), Seed	Developer of treatments for brain diseases with a focus on stroke and related conditions	$1.57M	JST, UntroD & 2 others	35/100